Bottom of the bill!

Looking forward to presenting on #testiclecancer and fertility today #EAU24 ….An important topic for all urologists who look after these men

A comprehensive piece on prostate cancer in the The Lancet, covering the value of screening, therapeutics, ethnic disparities and management in LMIC countries. hubs.li/Q02rYj6L0

Our breast cancer trials team Barts Experimental Cancer Medicine Centre are hosting a focus group in collaboration with The Christie NHS aiming to widen access to clinical trials for ethnically diverse communities.

Pleased to have co-edited this topic in Frontiers in Urology with my collaborators and friends Edward Christopher "Chris" Dee, MD, Dr. Brandon Mahal 🏁 and Gloryanne Aidoo-Micah. frontiersin.org/research-topic…. Great job Edward Christopher "Chris" Dee, MD for leading this initiative and giving voices to researchers from all corners of the world.

Pleased to share our research from 2 years as an Academic Clinical Fellow in the Kevin Litchfield TIGI lab! We unveil UTR-derived neoantigens as a promising source of neoantigens for personalized immunotherapy. Check out our findings and the PrimeCUTR tool: frontiersin.org/journals/immun…

bmjoncology.bmj.com/content/3/1/e0… A thoughtful piece from Prof Prof Ananya💙 and team.

Helps substantiate our consultations when asked ‘does reducing the dose of my ARTA affect my treatment?’

We’ve made substantial progress in #mhspc and #mcrpc treatment but important to focus on QOL too.

Diversity in Oncology Clinical Trials: Current Landscape for Industry-Sponsored Clinical Trials in Asia Read #openaccess here: link.springer.com/article/10.100…… #diversity #oncology #clinicaltrials

Great to be joining Kenrick Ng to support The Errol McKellar Foundation at their cancer support session in Walthamstow.

This group was set up to support African & Caribbean prostate cancer patients in the local area who were not accessing supplementary support service

In 2 weeks time at our next support group meeting Dr Shamash will be presenting a testosterone replacement therapy session. Please see the Facebook page for details Michelle Greenwood 💙 Shiv Smith 💙 Daniel Orchid JShamash Kenrick Ng UKONS #TesticularCancer

Strongly agree with Nick James

We are looking at this exact approach in LIBERTAS trial (NCT05884398). Now recruiting (very quickly!)

Neeraj Agarwal, MD, FASCO Mark Wildgust (he/him) Suneel Mundle Alicia Morgans, MD, MPH Tian Zhang, MD, MHS UroToday.com Simon C Karie Runcie, MD

Having a named specialist nurse makes a colossal difference to the management, journey and experience of a cancer patient. Agree that more resources need to be accorded to this key group of professionals.

Our international collaborative Data on the URO17 Bladder cancer biomarker from East and North Hertfordshire NHS Trust University of Hertfordshire🇬🇧 and King Hamad University Hospital, Bahrain 🇧🇭 published today

bmcurol.biomedcentral.com/articles/10.11…

BRCA carriers: consider lower PSA triggers for biopsy, MRI and biomarkers
Stacy Loeb, MD #MayoUroHawaii24

Goodbye for now SF. Thank you for a wonderful few days of networking and learning at #GU24 and I look forward to our next meetup in February 25!

Incredible findings at #ESMO23 : Prostate radiotherapy significantly reduces the long-term risk of obstructive uropathy in #mHSPC . This supports the use of radiotherapy in men at risk of upper urinary tract obstruction. Presented by Craig Jones > bit.ly/3SqZXPR Rashid K. Sayyid

Dr Matthew Young from Barts Experimental Cancer Medicine Centre presenting data on the predictive value of dynamic changes in ctDNA and baseline biomarkers with neoadjuvant atezolizumab in operable urothelial carcinoma. Data from the ABACUS trial. abstract 543. Tom Powles